ID27664A - Kombinasi antihipersensitif dari valsartan dan penghalang saluran kalsium - Google Patents
Kombinasi antihipersensitif dari valsartan dan penghalang saluran kalsiumInfo
- Publication number
- ID27664A ID27664A IDW20010051A ID20010051A ID27664A ID 27664 A ID27664 A ID 27664A ID W20010051 A IDW20010051 A ID W20010051A ID 20010051 A ID20010051 A ID 20010051A ID 27664 A ID27664 A ID 27664A
- Authority
- ID
- Indonesia
- Prior art keywords
- hypertension
- diabetic
- renal
- pharmaceutically acceptable
- primary
- Prior art date
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 2
- 229960004699 valsartan Drugs 0.000 title abstract 2
- 108090000312 Calcium Channels Proteins 0.000 title 1
- 102000003922 Calcium Channels Human genes 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 2
- 201000006370 kidney failure Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 206010003662 Atrial flutter Diseases 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000007530 Essential hypertension Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 206010020571 Hyperaldosteronism Diseases 0.000 abstract 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000003782 Raynaud disease Diseases 0.000 abstract 1
- 208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 206010039808 Secondary aldosteronism Diseases 0.000 abstract 1
- 206010042600 Supraventricular arrhythmias Diseases 0.000 abstract 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 206010061989 glomerulosclerosis Diseases 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11389398A | 1998-07-10 | 1998-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ID27664A true ID27664A (id) | 2001-04-19 |
Family
ID=22352165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IDW20010051A ID27664A (id) | 1998-07-10 | 1999-07-09 | Kombinasi antihipersensitif dari valsartan dan penghalang saluran kalsium |
Country Status (31)
| Country | Link |
|---|---|
| EP (3) | EP1096932B1 (cs) |
| JP (1) | JP2002520274A (cs) |
| KR (2) | KR100550167B1 (cs) |
| CN (2) | CN1733307A (cs) |
| AT (1) | ATE371448T1 (cs) |
| AU (1) | AU753486B2 (cs) |
| BE (1) | BE2016C011I2 (cs) |
| BR (1) | BR9912021A (cs) |
| CA (2) | CA2336822C (cs) |
| CY (4) | CY1107779T1 (cs) |
| CZ (2) | CZ304359B6 (cs) |
| DE (2) | DE122007000055I1 (cs) |
| DK (2) | DK2322174T3 (cs) |
| ES (2) | ES2552639T3 (cs) |
| FR (1) | FR16C0008I2 (cs) |
| HU (1) | HU229383B1 (cs) |
| ID (1) | ID27664A (cs) |
| IL (3) | IL140665A0 (cs) |
| LU (2) | LU91358I2 (cs) |
| NL (2) | NL300290I2 (cs) |
| NO (2) | NO331802B1 (cs) |
| NZ (2) | NZ509260A (cs) |
| PL (1) | PL194604B1 (cs) |
| PT (2) | PT1096932E (cs) |
| RU (3) | RU2450813C2 (cs) |
| SG (1) | SG142116A1 (cs) |
| SI (2) | SI1096932T1 (cs) |
| SK (1) | SK285863B6 (cs) |
| TR (1) | TR200100062T2 (cs) |
| WO (1) | WO2000002543A2 (cs) |
| ZA (1) | ZA200100232B (cs) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ304359B6 (cs) | 1998-07-10 | 2014-03-26 | Novartis Ag | Farmaceutická kombinační kompozice |
| HUP0104780A3 (en) | 1998-12-23 | 2002-11-28 | Novartis Ag | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| SK286859B6 (sk) * | 1999-04-28 | 2009-06-05 | Takeda Pharmaceutical Company Limited | Farmaceutický prípravok na predchádzanie, liečenie alebo inhibovanie vývoja jednoduchej retinopatie alebo predproliferačnej retinopatie |
| EP1867342A1 (en) * | 1999-07-21 | 2007-12-19 | Takeda Pharmaceutical Company Limited | Agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| WO2001015674A2 (en) | 1999-08-30 | 2001-03-08 | Aventis Pharma Deutschland Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| AU2001235363A1 (en) * | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Mibefradil analogues and their use |
| WO2001062741A1 (en) | 2000-02-25 | 2001-08-30 | South Alabama Medical Science Foundation | Tetrahydronaphtalene derivatives and their use |
| MXPA02010091A (es) * | 2000-04-12 | 2003-02-12 | Novartis Ag | Novedoso uso medico de inhibidores de sintasa de aldosterona solos o en combinacion con antagonistas del receptor at-1. |
| DE10018401A1 (de) * | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| US20060089389A1 (en) | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
| PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
| BR0108823A (pt) * | 2000-12-29 | 2002-12-10 | Osmotica Corp | Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva |
| ITMI20010129A1 (it) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
| JP2005509631A (ja) * | 2001-10-18 | 2005-04-14 | ノバルティス アクチエンゲゼルシャフト | Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩 |
| US20030180712A1 (en) * | 2002-03-20 | 2003-09-25 | Biostratum Ab | Inhibition of the beta3 subunit of L-type Ca2+ channels |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| US20040138306A1 (en) | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| SE0300988D0 (sv) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
| ES2334029T3 (es) | 2003-05-15 | 2010-03-04 | Roskamp Research Llc | Procedimiento para producir medicamentos para reducir la deposicion de amiloide, la neurotoxicidad de amiloide y la microgliosis. |
| CN1816533A (zh) * | 2003-05-16 | 2006-08-09 | 诺瓦提斯公司 | 包含缬沙坦的药物组合物 |
| RU2255740C2 (ru) * | 2003-07-02 | 2005-07-10 | Научно-исследовательский институт кардиологии Томского научного центра СО РАМН | Способ подбора дозы дилтиазема для лечения больных постинфарктным кардиосклерозом с недостаточностью кровообращения 2 функционального класса |
| US20050065094A1 (en) | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
| WO2005053687A1 (en) * | 2003-11-25 | 2005-06-16 | Novartis Ag | Combination of organic compounds |
| US20050209288A1 (en) * | 2004-01-12 | 2005-09-22 | Grogan Donna R | Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
| CN100364532C (zh) * | 2004-09-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 |
| WO2006109164A2 (en) | 2005-04-15 | 2006-10-19 | Research & Innovation Soc. Coop. A R.L. | A method for preventing, delaying or reverting abnormal amyloid deposition |
| GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| GB0520405D0 (en) * | 2005-10-07 | 2005-11-16 | Imp College Innovations Ltd | Biological agents and method |
| RU2008122712A (ru) * | 2005-11-08 | 2009-12-20 | Новартис АГ (CH) | Комбинация органических соединений |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| RU2329805C2 (ru) * | 2006-08-28 | 2008-07-27 | Илья Николаевич Медведев | Способ стабилизации эндотелиальной выстилки сосудов у больных метаболическим синдромом |
| KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
| RU2338527C1 (ru) * | 2007-02-26 | 2008-11-20 | Илья Николаевич Медведев | Способ коррекции высокой эндотелиоцитемии у лиц с метаболическим синдромом |
| RU2490014C2 (ru) | 2007-10-05 | 2013-08-20 | Альцгеймер'С Инститьют Оф Америка, Инк. | Способ уменьшения отложения амилоида, амилоидной нейротоксичности и микроглиоза с помощью (-)-энантиомера нилвадипина |
| CN101433536A (zh) * | 2007-11-12 | 2009-05-20 | 北京瑞康医药技术有限公司 | 含有烟酸氨氯地平和沙坦类药物的治疗组合物 |
| EP2240163A1 (en) * | 2007-12-31 | 2010-10-20 | Lupin Limited | Pharmaceutical compositions of amlodipine and valsartan |
| WO2010006103A1 (en) * | 2008-07-10 | 2010-01-14 | Ore Pharmaceuticals Inc. | Method for enhancing cognition or inhibiting cognitive decline |
| RU2382644C1 (ru) * | 2008-11-05 | 2010-02-27 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" | Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью |
| RU2398581C1 (ru) * | 2009-05-28 | 2010-09-10 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи (ФГУ РКНПК Росмедтехнологий) | Способ лечения больных гипертрофической кардиомиопатией |
| EP2536396B1 (en) | 2010-02-16 | 2016-08-10 | KRKA, D.D., Novo Mesto | Process for the preparation of oral solid dosage forms comprising valsartan |
| IT1400309B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso. |
| EA024096B1 (ru) * | 2011-04-12 | 2016-08-31 | Борюн Фармасьютикал Ко., Лтд. | Противогипертоническая фармацевтическая композиция |
| RU2014109074A (ru) | 2011-08-12 | 2015-09-20 | Бёрингер Ингельхайм Ветмедика Гмбх | ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ |
| WO2013147137A1 (ja) * | 2012-03-30 | 2013-10-03 | 味の素株式会社 | 心不全の治療剤 |
| CZ2013783A3 (cs) | 2013-10-08 | 2015-04-15 | Zentiva, K. S | Stabilní farmaceutická kompozice obsahující amlodipin a valsartan |
| WO2016073179A2 (en) * | 2014-10-23 | 2016-05-12 | The Trustees Of The University Of Pennsylvania | Novel chronotherapy based on circadian rhythms |
| RU2616213C2 (ru) * | 2015-07-10 | 2017-04-13 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) | Способ коррекции дисфункции факторов врожденного и адаптивного иммунитета при хронической почечной недостаточности в эксперименте |
| CN108289958A (zh) * | 2015-10-31 | 2018-07-17 | Io治疗公司 | 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱 |
| CN105287550A (zh) * | 2015-11-19 | 2016-02-03 | 哈尔滨圣吉药业股份有限公司 | 一种缬沙坦/非洛地平复方制剂及其制备方法 |
| US20230218583A1 (en) | 2020-04-17 | 2023-07-13 | Honeybrains, Llc | Compositions and methods for treating neuropsychiatric disorders |
| CN113730581A (zh) * | 2020-05-28 | 2021-12-03 | 杭州起岸生物科技有限公司 | 钾atp通道调节剂在制备抗糖尿病肾病药物中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4654372A (en) * | 1986-01-10 | 1987-03-31 | Warner-Lambert Company | Method for using verapamil for treating stroke |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| DE59107440D1 (de) * | 1990-02-19 | 1996-04-04 | Ciba Geigy Ag | Acylverbindungen |
| NZ242724A (en) | 1991-05-15 | 1994-09-27 | Du Pont | Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker |
| US5492904A (en) * | 1991-05-15 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
| WO1993017682A1 (en) * | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| DE69313650T2 (de) * | 1992-07-27 | 1998-01-08 | Nps Pharma Inc | Calcium-kanal blockierende polypeptide aus agelenopsis aperta |
| US5264447A (en) * | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
| US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| DK0634175T3 (da) * | 1993-07-15 | 2001-04-30 | Hoffmann La Roche | Farmaceutisk kombination, der indeholder en hæmmer af renin-angiotensin-systemet og en endothelin-antagonist |
| ATE300287T1 (de) * | 1994-02-08 | 2005-08-15 | Novartis Pharma Gmbh | Behandlung von normaldruckglaukom mit valsartan |
| PL316259A1 (en) * | 1994-03-17 | 1997-01-06 | Ciba Geigy Ag | Treatment of diabetic nephropathy with valsartan |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| CZ304359B6 (cs) | 1998-07-10 | 2014-03-26 | Novartis Ag | Farmaceutická kombinační kompozice |
-
1999
- 1999-07-09 CZ CZ2007-647A patent/CZ304359B6/cs not_active IP Right Cessation
- 1999-07-09 KR KR1020017000323A patent/KR100550167B1/ko not_active Expired - Fee Related
- 1999-07-09 HU HU0102828A patent/HU229383B1/hu active Protection Beyond IP Right Term
- 1999-07-09 PT PT99934647T patent/PT1096932E/pt unknown
- 1999-07-09 BR BR9912021-6A patent/BR9912021A/pt not_active IP Right Cessation
- 1999-07-09 PT PT101770931T patent/PT2322174E/pt unknown
- 1999-07-09 EP EP99934647A patent/EP1096932B1/en not_active Revoked
- 1999-07-09 DK DK10177093.1T patent/DK2322174T3/en active
- 1999-07-09 DE DE200712000055 patent/DE122007000055I1/de active Pending
- 1999-07-09 ES ES10177093.1T patent/ES2552639T3/es not_active Expired - Lifetime
- 1999-07-09 CA CA002336822A patent/CA2336822C/en not_active Expired - Lifetime
- 1999-07-09 KR KR10-2004-7011566A patent/KR20040078140A/ko not_active Ceased
- 1999-07-09 SI SI9930996T patent/SI1096932T1/sl unknown
- 1999-07-09 ID IDW20010051A patent/ID27664A/id unknown
- 1999-07-09 PL PL99345897A patent/PL194604B1/pl unknown
- 1999-07-09 CZ CZ20010087A patent/CZ299429B6/cs unknown
- 1999-07-09 CA CA2678722A patent/CA2678722C/en not_active Expired - Lifetime
- 1999-07-09 WO PCT/EP1999/004842 patent/WO2000002543A2/en active IP Right Grant
- 1999-07-09 SK SK31-2001A patent/SK285863B6/sk not_active IP Right Cessation
- 1999-07-09 TR TR2001/00062T patent/TR200100062T2/xx unknown
- 1999-07-09 RU RU2001102585/15A patent/RU2450813C2/ru active Protection Beyond IP Right Term
- 1999-07-09 SG SG200300082-5A patent/SG142116A1/en unknown
- 1999-07-09 DK DK99934647T patent/DK1096932T3/da active
- 1999-07-09 AU AU50349/99A patent/AU753486B2/en not_active Expired
- 1999-07-09 RU RU2001102585/15K patent/RU2243768C2/ru active
- 1999-07-09 DE DE69936992T patent/DE69936992T2/de not_active Expired - Lifetime
- 1999-07-09 CN CNA200510072738XA patent/CN1733307A/zh active Pending
- 1999-07-09 EP EP10177093.1A patent/EP2322174B1/en not_active Revoked
- 1999-07-09 AT AT99934647T patent/ATE371448T1/de active
- 1999-07-09 CN CNB998097764A patent/CN1234357C/zh not_active Expired - Lifetime
- 1999-07-09 NZ NZ509260A patent/NZ509260A/en not_active IP Right Cessation
- 1999-07-09 SI SI9931078T patent/SI2322174T1/sl unknown
- 1999-07-09 JP JP2000558803A patent/JP2002520274A/ja active Pending
- 1999-07-09 NZ NZ527598A patent/NZ527598A/xx not_active IP Right Cessation
- 1999-07-09 IL IL14066599A patent/IL140665A0/xx unknown
- 1999-07-09 EP EP07105179A patent/EP1870098A3/en not_active Withdrawn
- 1999-07-09 ES ES99934647T patent/ES2289814T3/es not_active Expired - Lifetime
-
2001
- 2001-01-01 IL IL140665A patent/IL140665A/en unknown
- 2001-01-08 NO NO20010113A patent/NO331802B1/no not_active IP Right Cessation
- 2001-01-09 ZA ZA200100232A patent/ZA200100232B/en unknown
-
2007
- 2007-09-06 LU LU91358C patent/LU91358I2/fr unknown
- 2007-09-10 NL NL300290C patent/NL300290I2/nl unknown
- 2007-10-25 CY CY20071101384T patent/CY1107779T1/el unknown
- 2007-10-30 CY CY200700026C patent/CY2007026I1/el unknown
-
2011
- 2011-07-04 IL IL213926A patent/IL213926A0/en unknown
-
2012
- 2012-03-20 RU RU2012110522/15A patent/RU2012110522A/ru unknown
- 2012-07-03 NO NO2012013C patent/NO2012013I2/no unknown
-
2015
- 2015-10-06 CY CY20151100890T patent/CY1116770T1/el unknown
-
2016
- 2016-03-07 CY CY2016006C patent/CY2016006I2/el unknown
- 2016-03-07 LU LU92992C patent/LU92992I2/xx unknown
- 2016-03-07 BE BE2016C011C patent/BE2016C011I2/nl unknown
- 2016-03-07 NL NL300800C patent/NL300800I2/nl unknown
- 2016-03-07 FR FR16C0008C patent/FR16C0008I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ID27664A (id) | Kombinasi antihipersensitif dari valsartan dan penghalang saluran kalsium | |
| NL300811I2 (cs) | ||
| EP1507558B8 (en) | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |